Division of Hematology Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.
Curr Osteoporos Rep. 2023 Aug;21(4):323-329. doi: 10.1007/s11914-023-00798-3. Epub 2023 Jun 9.
Bone is a common site of metastatic spread for solid tumors. Bone as an organ serves unique roles in the body's structural integrity, hematopoiesis, and the development of immune modulating cells. With the increasing use of immunotherapy, specifically immune checkpoint inhibitors, understanding the response of bone metastases is necessary.
The data on checkpoint inhibitors used for managing solid tumors are reviewed here with a focus on bone metastases. Albeit with limited available data, there is a trend toward poorer outcomes in this setting, presumably due to the unique immune microenvironment within bone and bone marrow. Despite the potential to improve cancer outcomes with use of ICIs, bone metastases remain challenging to manage and may have different responses to ICIs than other disease sites. Areas for future investigation include a nuanced understanding of the bone microenvironment and dedicated research aimed at specific bone metastases outcomes.
骨骼是实体瘤转移的常见部位。骨骼作为一个器官，在维持身体结构完整性、造血和免疫调节细胞发育方面具有独特的作用。随着免疫疗法，特别是免疫检查点抑制剂的应用日益增多，了解骨转移的反应是必要的。
本文综述了用于治疗实体瘤的检查点抑制剂的数据，重点关注骨转移。尽管可用数据有限，但在这种情况下的结果往往较差，推测可能是由于骨骼和骨髓内独特的免疫微环境所致。尽管免疫检查点抑制剂的应用有可能改善癌症的预后，但骨转移仍然难以治疗，并且对免疫检查点抑制剂的反应可能与其他疾病部位不同。未来的研究领域包括对骨骼微环境的细致了解，以及针对特定骨转移结局的专门研究。
